Event JSON
{
"id": "e47014787b1f9525f12bb22042701fd4f798f47967437a169a4d886845a9d1ab",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1749013740,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/why-biontech-stock-soared-today-173846263.html"
],
[
"subject",
"Why BioNTech Stock Soared Today"
],
[
"published_at",
"1748885926"
],
[
"image",
"https://media.zenfs.com/en/motleyfool.com/c9bee2ecaed8dd46d01b9c27d57adba7"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/motleyfool.com/c9bee2ecaed8dd46d01b9c27d57adba7"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327, which is already in phase 3 trials. The partnership will see the two companies split the costs of developing and commercializing the drug, with Bristol paying BioNTech $1.5 billion upfront and up to $11 billion over time. The drug has the potential to treat multiple types of cancer, including breast and lung cancer."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://media.zenfs.com/en/motleyfool.com/c9bee2ecaed8dd46d01b9c27d57adba7\n\nhttps://finance.yahoo.com/news/why-biontech-stock-soared-today-173846263.html",
"sig": "2a66a16f1f74246799fa28c5302b0011fc7c1ac16c91135d6638ca22879ca5e3a37f79cecb586cee43c430146af555ac9dcd3285cb1a72de700c957a299369a5"
}